Specialty Pharmacy

DNA and RNA sequencing could provide insight about resistance to chemotherapy in patients suffering from triple-negative breast cancer.

Test can evaluate whether a patient with lymphoma will respond to CAR T-cell therapy, which could lead to better and longer lasting treatment options.

The phase 2 AXIOMATIC trials assessing milvexian met its primary endpoints, with researchers anticipating a phase 3 trial to come within the year.

An overview of the legal and business tools available to community, specialty, hospital, and health-system pharmacies in seeking to maintain payer network access and combat abusive practices.

The FDA approval makes olipudase alfa the first approved drug to target the physiological symptoms of the disease.

Vertical and horizontal consolidation has had a significant impact on retail, specialty, and health-system pharmacies.

Ozanimod (Zeposia) is indicated for the treatment of multiple sclerosis and moderately to severely active ulcerative colitis in adults.

Atezolizumab meets its primary endpoint of overall survival for patients with resected non-small cell lung cancer across most subgroups.

Study evaluates efficacy, immunogenicity, safety of the product to eculizumab in patients with paroxysmal nocturnal hemoglobinuria.

As more biosimilars and specialty generics enter the market next year, this could result in a shift in drug spending.

Pemigatinib is the first targeted therapy to gain FDA approval for the treatment of adult patients with relapsed or refractory myeloid/lymphoid neoplasms with FGFR1 rearrangement.

Yoona Kim, PharmD, PhD, co-founder and CEO of Arine, discusses some of the key takeaways from the launch of Mark Cuban's pharmacy Mark Cuban Cost Plus Drug Co.

Risk factors associated with declining health-related quality of life for adult survivors of childhood cancer, such as physical inactivity and chronic health conditions, should be targets of surveillance and intervention.

Canakinumab did not meet the primary endpoint of disease-free survival in adult patients with stages II-IIIA and IIIB completely resected non-small cell lung cancer.

Overall rates of early-stage cervical cancer in the United States have been falling, but cases with advanced disease are continuing to rise.

Ibrutinib (Imbruvica) is the first therapy to gain FDA approval for younger patients who had no prior treatment options for chronic graft-versus-host disease.

Zynteglo is an autologous hematopoietic stem cell-based gene therapy indicated for the treatment of adult and pediatric patients with β-thalassemia who require regular red blood cell transfusions.

Long-term follow up on the KEYNOTE-604 study suggests pembrolizumab plus etoposide/platinum is a superior first-line therapy for small cell lung cancer vs placebo.

In New York’s medical cannabis program, research showed that patients’ preference around potency differed among users, regardless of their health conditions.

Irinotecan liposomal injection (Onivyde) used as second-line therapy for patients with small cell lung cancer did not meet the primary end point of overall survival compared to topotecan.

Narcissistic leaders have a negative impact on the culture of their organization as their conduct and management style induces fear.

Oncology pharmacists must think critically about the digital experience they give patients.

Andrew Barnell, MBA, CEO and co-founder of Geneoscopy, discusses his meeting at the White House on President Biden’s Cancer Moonshot initiative.

Researchers suggest that immune checkpoint inhibitors significantly preserve the quality of life in patients with cancer.

For pediatric patients with B-cell acute lymphoblastic leukemia, higher doses of tisagenlecleucel increased their rate of survival after 1 year by nearly 30%.

Zynteglo was approved for the treatment of adult and pediatric patients with beta-thalassemia who require regular red blood cell transfusions after safety and efficacy were demonstrated in clinical trials.

FDA approved dexamethasone tablets USP 1.5mg, 4mg and 6mg, providing a new generic alternative to the steroid Decadron.

Gilead Sciences Inc submitted a supplemental Biologics License Application to the FDA for sacituzumab govitecan-hziy (Trodelvy) following promising trial results.